Summary Tumour necrosis factor (TNF) has been found to be an important immunomodulator. Among other functions TNF activates natural killer (NK) cells and stimulates monocytes/macrophages in an autocrine fashion. TNF production and NK activity in peripheral blood mononuclear cells were determined in a clinical phase I study in which recombinant human (rh) TNF was administered as a continuous infusion weekly for a period of 8 weeks. Even though TNF production and NK activity were significantly reduced directly after rhTNF infusion the effect proved to be transient and most pronounced at the first rhTNF administration. One day after completion of the rhTNF infusion the peripheral cells released more TNF into the supernatant compared to TNF activity immediately before the rhTNF infusion. This effect was conspicuous in nonstimulated cultures. After repeated rhTNF infusions both stimulated and non-stimulated TNF production of the peripheral blood mononuclear cells was increased. NK cell activity was also enhanced after repeated cycles of rhTNF administration as compared to early rhTNF treatment. Thus, repeated rhTNF infusions lead to a stimulatory effect on TNF production and NK activity of peripheral blood cells.
Lymphocytes and macrophages release an array of soluble mediators (cytokines) which affect immune responses. The major activities of some of these mediators are activation of cells and the induction or support of proliferative or suppressive effects. Most of the structurally defined mediators have a broad sprectrum of activities overlapping with functions of other mediators. Activated macrophages release inflammatory mediators like interleukin 1 (ILl) and tumour necrosis factor (TNF) which both have a pleiotropic mode of action. In vivo, TNF induces fever, hypotension, leukopenia, local tissue necrosis (Chapman et al., 1987) and can lead to a vascular leak syndrome (Remick et al., 1987 Dinarello (1987) . Many of the endotoxic effects of TNF and ILl come about by the interaction of the mediators with endothelial cells. TNF and ILl damage the endothelial cell layer, induce PGE2 and platelet activating factor production, procoagulant activity, leukocyte adherence and plasminogen activator inhibitor (Dinarello, 1987) . (Philip & Epstein, 1986; Bachwich et al., 1986; Hensel et al., 1987) and enhanced NK activity (Ostensen et al., 1987) (Andus et al., 1987) . The pyrogen content was less than 1.3ngmg-' protein.
Preparation of PMNL
Human PMNL were prepared from heparinised blood samples by Ficoll-Paque (Pharmacia, Freiburg, FRG) density gradient centrifugation.
Determination of TNF production capacity PMNL (2 x 106ml-') were cultured in duplicates in RPMI1640 (Gibco), with 10% heat inactivated fetal calf serum (Gibco) for 20 h either with or without 10 lg ml-' Staphylococcus aureus (Staph.a., Pansorbin, Calbiochem, Frankfurt, FRG). Cell-free supernatants were harvested and stored at -20°C until they were tested for TNF activity.
TNF activity was determined in duplicates by an enzymelinked immunospecific assay (ELISA) as described recently (Kist et al., 1988) . The standard deviation was always < 3%.
TNF content was expressed as ng ml-'. The lowest amount of TNF detectable with this assay was 340 ± 180 pg ml-'.
Determination of NK activity NK activity in the PMNL was determined as described recently (Kist et al., 1988) . Briefly, % specific lysis of 5"Crlabelled target cells (K562 tumour cells) by the PMNL was determined in triplicate cultures at effector to target ratios of 10:1, 5:1, and 2.5:1 after 4h of incubation. The standard deviation was always < 5%.
RNA extraction and dot blot analyses The procedure has been described in detail recently (Cheley & Anderson, 1984 (Pharmacia, Freiburg, FRG) . The TNF-cDNA probe consisted of a 425 bp PstI-fragment of the non-translated 3'-region of human TNF and was obtained from BASF, Ludwigshafen, FRG. The human P-actin-cDNA probe is described by Moos and Gallwitz (1983) and consists of an 560 bp SalI-EcoRI cDNA fragment.
Statistics
Statistical analyses of the data pairs from individual patients obtained before and after rhTNF treatment were performed using the Wilcoxon rank sum test. P values were calculated for assessment of significance.
Results TNF production capacity of seven patients was determined during 31 cycles of rhTNF treatment. The PMNL cultures were set up directly before rhTNF infusion and immediately after the infusion. Patients 1-3 were on the schedule with one rhTNF infusion per week, patients 4-7 received two rhTNF infusions per week. Whereas in most patients TNF production decreased immediately after the first rhTNF treatment (with exception of patients 2 and 5) as described recently (Kist et al., 1988 ) the changes were not so clear after repeated rhTNF infusions. TNF levels from non-stimulated cultures immediately after rhTNF infusion were not lower compared to pretreatment values in most patients after consecutive rhTNF cycles. Only in seven out of 24 such cultures were TNF levels reduced. About half of the cultures consisting of cells cultured after repeated rhTNF treatment generated even higher TNF levels compared to the values immediately before rhTNF infusion (11 out of 24). Only about half (14 out of 23) of the Staph.a.-stimulated cultures from patients who had received rhTNF more than once developed reduced TNF values immediately after rhTNF infusion during therapy. In eight out of 23 of such stimulated cultures TNF production was enhanced immediately after rhTNF infusion (data not shown).
Improvement of the TNF production before each subsequent rhTNF infusion as compared to the baseline values before the very first rhTNF treatment was found in the course of rhTNF treatment. In all patients the TNF production capacity of unstimulated cells as well as a Stapha.a.-stimulated cells (with the exception of patient 7) increased during therapy (Figure 1) . TNF values were significantly higher compared to TNF values before any treatment in 17 out of 24 (71%) treatment cycles in unstimulated cultures (P = 0.014) and in 14 out of 23 (61%) cycles in stimulated cultures (P = 0.129). Spontaneous TNF production capacity of all patients was enhanced at some point during rhTNF therapy.
In three patients TNF production was determined 24 hours after completion of the rhTNF infusion in seven treatment cycles (Figure 2) . In all but one of the unstimulated cultures the TNF production increased 24 h after completion of the infusion and more TNF activity was generated compared to the pretreatment values. In one culture the level of TNF produced was unchanged before and 24 h after completion of the rhTNF infusion. The increase of the TNF levels produced by unstimulated cultures was statistically significant (P = 0.158). When the cultures were stimulated with Staph.a., three cultures generated higher TNF values, two cultures produced lower TNF values and one was unchanged 24 h after rhTNF infusion (P = 0.53 1).
From PMNL samples of one patient (patient 5) mRNA was extracted before, directly after and 24 h after rhTNF infusion in four treatment cycles. In all four cycles the signal for TNF specific mRNA was strongest 24 h after rhTNF infusion. Control hybridisation with a human P-actin probe showed that about equal amounts of RNA had been applied to the filter (data not shown).
NK activity was determined in subsequent cycles of therapy before and immediately after rhTNF infusion in four patients. Again, as already described (Kist et al., 1988 ) the NK levels immediately after 24 h of continuous infusion of rhTNF were always lower compared to the respective NK value measured before the rhTNF infusion in the same cycle. However, in all tested cases NK activity significantly increased (P = 0.047) in the course of rhTNF therapy ( Figure  3 ). TNF with high affinity have recently been described on human monocytes (Imamura et al., 1987) . Considering the activating function of TNF on human monocytes and also on NK cells it was surprising to see reduced monokine production and NK activity in patients immediately after rhTNF infusion (Kist et al., 1988) . The reduction of monokine production and NK activity might be explained by the loss of monocytes and NK cells from the circulation as a consequence of the enhanced leukocyte adherence to the endothelium after TNF (Bevilacqua et al., 1987 Figure 3 NK activity of PMNL during rhTNF therapy. NK activity was determined in PMNL cultures from patient 4 in weeks I and 6, from patient 6 in weeks I and 2, from patient 7 in weeks 2, 5 and 7, and from patient 8 in weeks I and 2 before (open bars) and after (hatched bars) rhTNF infusion.
